Medilink Therapeutics (suzhou) Co., Ltd.

This study is testing a new drug called YL201 in combination with an existing cancer therapy (atezolizumab) for people with advanced small cell lung cancer who haven't had prior treatment. The main goals are to find a safe and effective dose and to see how well the combination wo…

This study is testing a new drug called YL202 for people with a specific type of advanced breast cancer that has stopped responding to chemotherapy. It will compare YL202 against several standard treatment options to see which is better at controlling the cancer and helping patie…

This study compares an experimental drug called YL202 against the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). It's for patients whose cancer has continued to grow despite trying two other …